Nautilus Biotechnology (NASDAQ:NAUT) said it is shifting a significant share of its research and development resources toward proteoform applications, citing customer interest and a delay in its Broadscale broad-proteome program. Chief Executive Officer Sujal Patel said the company’s platform has d
$NAUT
Price history, market instrument context, member research, and related headlines in one place.
NAUT key statistics
NasdaqCMUSD
52-week range
$0.84138%$4.31
Latest session $1.88–$2.20Nautilus Biotechnology, Inc. (NAUT) is a stock instrument quoted on NasdaqCM in USD. The most recently published price is $2.16, up $0.00 (0.00%) from the previous close of $2.16. It has traded between $1.88 and $2.20 in the latest session. Over the past year it has ranged from $0.841 to $4.31, leaving it in the lower half of its 52-week range (38%). Reported volume for the session was 8.5M. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
Source-linked intelligence
Related news
Nautilus Biotechnology GAAP EPS of -$0.11 beats by $0.03, revenue of $0.19M — See source for full details.
Loading $NAUT research…